BISMUTH CHEWABLE TABLETS 308 MG
CALCIUM CARBONATE : 308 MG BISMUTH SUBSALICYLATE : 262 MG · DIN 02243124 · VITA HEALTH PRODUCTS INC
Health Canada status: CANCELLED POST MARKET
What is BISMUTH CHEWABLE TABLETS?
BISMUTH CHEWABLE TABLETS 308 MG contains CALCIUM CARBONATE : 308 MG BISMUTH SUBSALICYLATE : 262 MG. It is listed in the Health Canada Drug Product Database under DIN 02243124, held by VITA HEALTH PRODUCTS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 26-Jul-2004. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02243124 |
|---|---|
| Brand name | BISMUTH CHEWABLE TABLETS |
| Generic / active ingredient | CALCIUM CARBONATE : 308 MG BISMUTH SUBSALICYLATE : 262 MG |
| Manufacturer | VITA HEALTH PRODUCTS INC |
| Strength | 308 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A02AX ANTACIDS, OTHER COMBINATIONS |
| AHFS class | 56:04.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 26-Jul-2004 |
| Original market date | 2001-04-01 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A02AX ANTACIDS, OTHER COMBINATIONS. 2 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PEPTO-BISMOL CHEWABLES | 350 MG | TABLET (CHEWABLE) | PROCTER & GAMBLE INC | MARKETED | DIN 02237315 |
| STOMACH RELIEF CHEWABLE TABLETS | 262 MG | TABLET (CHEWABLE) | GUARDIAN DRUG COMPANY INC | MARKETED | DIN 02389215 |
| ANTACID 2 TABLETS | 61 MG | TABLET | ADVERTISING UNLIMITED INC. (A.U.I.) | CANCELLED POST MARKET | DIN 01904310 |
| BISMED CHEWABLE TABLETS | 350 MG | TABLET | TECHNILAB PHARMA INC. | CANCELLED POST MARKET | DIN 00810509 |
| BISMUTH + ANTACID (CHEWABLE TABLETS) | 262 MG | TABLET (CHEWABLE) | PERRIGO INTERNATIONAL | CANCELLED POST MARKET | DIN 02240473 |
| BISMUTH TABLETS WITH CALCIUM CARBONATE | 350 MG | TABLET (CHEWABLE) | TANTA PHARMACEUTICALS INC | APPROVED | DIN 02317117 |
| CHERRY FLAVOUR PEPTO-BISMOL TAB | 262 MG | TABLET | PROCTER & GAMBLE INC | CANCELLED POST MARKET | DIN 01983725 |
| CHEWABLE BISMUTH TABLETS WITH CALCIUM CARBONATE | 262 MG | TABLET (CHEWABLE) | CELLCHEM PHARMACEUTICALS INC. | DORMANT | DIN 02319888 |
| MUCAINE - SUS | 100 MG / 5 ML | SUSPENSION | AURIUM PHARMA INC. | CANCELLED POST MARKET | DIN 02125013 |
| PEPTO-BISMOL TAB | 262 MG | TABLET | RICHARDSON-VICKS, DIVISION OF THE PROCTER & GAMBLE COMPANY | CANCELLED POST MARKET | DIN 00879037 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.